53 withdrawn. 53 Phase 1, 20 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 53 | Withdrawn 53 |
| Phase 2 | 20 | Withdrawn 20 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2026-04-01 | 2026-05-15 | |
| A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia TER-1754, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 | Withdrawn | Terremoto Biosciences Inc. | 2025-12-15 | 2026-04-13 | |
| UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma UF-KURE-BCMA CAR T-cells, Cyclophosphamide, Fludarabine - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Withdrawn | David Wald | 2025-09-01 | 2026-05-13 | |
| Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells Commercial CAR-T, Investigational CAR-T - Malignancy, Cancer | Phase 1 / Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2025-01-20 | 2026-01-06 | |
| A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors 225Ac-DOTATATE - Multiple Myeloma, Refractory, Multiple Myeloma in Relapse | Phase 1 | Withdrawn | Jules Bordet Institute | 2024-10-01 | 2025-01-31 | |
| CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-03-28 | 2024-05-01 | |
| Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Melphalan, Peripheral Blood Stem Cell Transplantation - Plasma Cell Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2024-01-27 | 2024-01-31 | |
| An Open Label, Single-arm Clinical Study Evaluating the Safety and Efficacy of ICI201 Infusion in Relapsed/Refractory Multiple Myeloma ICI201 - Relapsed/Refractory Multiple Myeloma | Phase 1 | Withdrawn | The First Affiliated Hospital of Soochow University | 2023-10-09 | 2023-12-22 | |
| Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma Mezigdomide, Ixazomib, Dexamethasone - Relapsed and Refractory Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | Kathleen Dorritie | 2023-10-02 | 2024-11-19 | |
| A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) AMG 701 - Relapsed/Refractory Multiple Myeloma | Phase 1 | Withdrawn | Amgen | 2023-08-29 | 2022-09-27 | |
| mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM) mRNA-2736 - Relapsed or Refractory Multiple Myeloma | Phase 1 | Withdrawn | ModernaTX, Inc. | 2023-08-15 | 2023-08-18 | |
| Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma SLAMF7 FPBMC - Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | University of Virginia | 2023-08-01 | 2023-11-21 | |
| Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases LM-305, Dexamethasone - Relapsed or Refractory Multiple Myeloma, Other Plasma Cell Diseases | Phase 1 / Phase 2 | Withdrawn | LaNova Medicines Limited | 2023-01-18 | 2023-11-18 | |
| Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma. Pembrolizumab, Belantamab mafodotin, Dexamethasone - Multiple Myeloma, Refractory | Phase 1 / Phase 2 | Withdrawn | Hackensack Meridian Health | 2022-12-01 | 2023-01-27 | |
| Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM Daratumumab, Pomalidomide - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | Alliance Foundation Trials, LLC. | 2022-10-01 | 2023-01-27 | |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Lenalidomide, Ublituximab, Umbralisib - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 1 | Withdrawn | Yazeed Sawalha | 2022-09-30 | 2022-09-30 | |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL HMPL-760 - CLL/SLL, NHL | Phase 1 | Withdrawn | Hutchmed | 2022-02-15 | 2023-02-21 | |
| The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Camostat Mesylate, Microcrystalline Cellulose, NF - Coagulopathy, Cardiovascular Complication | Phase 1 / Phase 2 | Withdrawn | Yale University | 2021-11-01 | 2022-05-18 | |
| INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma Pomalidomide, Dexamethasone, INCB053914 50 mg bis in die (BID) - Refractory Multiple Myeloma, Relapse Multiple Myeloma | Phase 1 | Withdrawn | Medical College of Wisconsin | 2021-07-01 | 2020-08-19 |
Showing 20 of 53. Sign in to see all of them.
Multiple Myeloma (44) · Lymphoma, B-Cell, Marginal Zone (8) · Lymphoma, Mantle-Cell (8) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma, Follicular (7) · Lymphoma, Non-Hodgkin (7) · Recurrence (7) · Waldenstrom Macroglobulinemia (7) · Lymphoma (6) · Lymphoma, Large B-Cell, Diffuse (6) · Burkitt Lymphoma (5) · Leukemia, Myeloid, Acute (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Leukemia (4) · Lymphoma, Large-Cell, Immunoblastic (4)
Cardiovascular Diseases (53) · Hemic and Lymphatic Diseases (53) · Hemorrhagic Disorders (53) · Vascular Diseases (53) · Hematologic Diseases (52) · Blood Protein Disorders (50) · Immune System Diseases (50) · Immunoproliferative Disorders (50) · Neoplasms by Histologic Type (50) · Paraproteinemias (50) · Lymphoproliferative Disorders (49) · Neoplasms (49) · Neoplasms, Plasma Cell (47) · Pathologic Processes (18)
Dexamethasone (15) · Calcium Dobesilate (9) · Bortezomib (8) · Lenalidomide (8) · Cyclophosphamide (6) · Melphalan (6) · Leukapheresis (3) · Magnetic Resonance Spectroscopy (3) · auricularum (3) · daratumumab (3) · dexamethasone 21-phosphate (3) · dexamethasone acetate (3) · fludarabine (3) · fludarabine phosphate (3) · pomalidomide (3)
Dana-Farber Cancer Institute (2) · Fred Hutchinson Cancer Center (2) · Jonsson Comprehensive Cancer Center (2) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · University of Arkansas (2) · AbbVie (1) · Alliance Foundation Trials, LLC. (1) · Alliance for Clinical Trials in Oncology (1) · Amgen (1) · Barbara Ann Karmanos Cancer Institute (1) · Bayer (1) · Bellicum Pharmaceuticals (1) · Bristol-Myers Squibb (1)
United States (25) · Australia (3) · Belgium (2) · Canada (2) · China (2) · Greece (2) · Israel (2) · Italy (2) · South Korea (2) · Spain (2) · Czechia (1) · France (1) · Germany (1) · Netherlands (1) · Poland (1)
Andrew J. Yee, MD (1) · Arya Mani, MD (1) · Binod Dhakal, MD (1) · Damian J. Green (1) · Depei Wu (1) · Elisabet E. Manasanch, MD (1) · Frits van Rhee, MD, PhD (1) · George Somlo, MD (1) · Grzegorz Nowakowski (1) · Hamza Hassan (1) · Jacalyn Rosenblatt, MD (1)
2015 (1), 2016 (1), 2023 (1), P01CA078902 (1), P30CA015083 (1), P30CA022453 (1), R01CA205248 (1), U10CA180820 (1), UM1CA186644 (1)